Literature DB >> 35771560

Ceramide: improving Bcl-2 inhibitor therapy.

Brian M Barth1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35771560      PMCID: PMC9247366          DOI: 10.1182/blood.2022016608

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  10 in total

1.  Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia.

Authors:  Brian M Barth; Weiyuan Wang; Paul T Toran; Todd E Fox; Charyguly Annageldiyev; Regina M Ondrasik; Nicole R Keasey; Timothy J Brown; Viola G Devine; Emily C Sullivan; Andrea L Cote; Vasiliki Papakotsi; Su-Fern Tan; Sriram S Shanmugavelandy; Tye G Deering; David B Needle; Stephan T Stern; Junjia Zhu; Jason Liao; Aaron D Viny; David J Feith; Ross L Levine; Hong-Gang Wang; Thomas P Loughran; Arati Sharma; Mark Kester; David F Claxton
Journal:  Blood Adv       Date:  2019-09-10

Review 2.  Ceramide-orchestrated signalling in cancer cells.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Nat Rev Cancer       Date:  2012-12-13       Impact factor: 60.716

3.  Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.

Authors:  Alexander C Lewis; Victoria S Pope; Melinda N Tea; Manjun Li; Gus O Nwosu; Thao M Nguyen; Craig T Wallington-Beddoe; Paul A B Moretti; Dovile Anderson; Darren J Creek; Maurizio Costabile; Saira R Ali; Chloe A L Thompson-Peach; B Kate Dredge; Andrew G Bert; Gregory J Goodall; Paul G Ekert; Anna L Brown; Richard D'Andrea; Nirmal Robinson; Melissa R Pitman; Daniel Thomas; David M Ross; Briony L Gliddon; Jason A Powell; Stuart M Pitson
Journal:  Blood       Date:  2022-06-30       Impact factor: 25.476

4.  Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML.

Authors:  Mohammed Dany; Salih Gencer; Rose Nganga; Raquela J Thomas; Natalia Oleinik; Kyla D Baron; Zdzislaw M Szulc; Peter Ruvolo; Steven Kornblau; Michael Andreeff; Besim Ogretmen
Journal:  Blood       Date:  2016-08-18       Impact factor: 22.113

5.  Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.

Authors:  Samy A F Morad; Terence E Ryan; P Darrell Neufer; Tonya N Zeczycki; Traci S Davis; Matthew R MacDougall; Todd E Fox; Su-Fern Tan; David J Feith; Thomas P Loughran; Mark Kester; David F Claxton; Brian M Barth; Tye G Deering; Myles C Cabot
Journal:  J Lipid Res       Date:  2016-05-02       Impact factor: 5.922

6.  Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.

Authors:  Jason A Powell; Alexander C Lewis; Wenying Zhu; John Toubia; Melissa R Pitman; Craig T Wallington-Beddoe; Paul A B Moretti; Diana Iarossi; Saumya E Samaraweera; Nik Cummings; Hayley S Ramshaw; Daniel Thomas; Andrew H Wei; Angel F Lopez; Richard J D'Andrea; Ian D Lewis; Stuart M Pitson
Journal:  Blood       Date:  2016-12-12       Impact factor: 22.113

7.  Integrated Stress Response Activity Marks Stem Cells in Normal Hematopoiesis and Leukemia.

Authors:  Peter van Galen; Nathan Mbong; Antonia Kreso; Erwin M Schoof; Elvin Wagenblast; Stanley W K Ng; Gabriela Krivdova; Liqing Jin; Hiromitsu Nakauchi; John E Dick
Journal:  Cell Rep       Date:  2018-10-30       Impact factor: 9.423

Review 8.  BCL2 and MCL1 inhibitors for hematologic malignancies.

Authors:  Andrew W Roberts; Andrew H Wei; David C S Huang
Journal:  Blood       Date:  2021-09-30       Impact factor: 22.113

9.  Acid ceramidase is upregulated in AML and represents a novel therapeutic target.

Authors:  Su-Fern Tan; Xin Liu; Todd E Fox; Brian M Barth; Arati Sharma; Stephen D Turner; Andy Awwad; Alden Dewey; Kenichiro Doi; Barbara Spitzer; Mithun Vinod Shah; Samy A F Morad; Dhimant Desai; Shantu Amin; Junjia Zhu; Jason Liao; Jong Yun; Mark Kester; David F Claxton; Hong-Gang Wang; Myles C Cabot; Edward H Schuchman; Ross L Levine; David J Feith; Thomas P Loughran
Journal:  Oncotarget       Date:  2016-12-13

10.  A novel mechanism of thrombocytopenia by PS exposure through TMEM16F in sphingomyelin synthase 1 deficiency.

Authors:  Yoritaka Fujii; Makoto Taniguchi; Shingo Nagaya; Yoshibumi Ueda; Chieko Hashizume; Ken Watanabe; Hiroyuki Takeya; Takeo Kosaka; Toshiro Okazaki
Journal:  Blood Adv       Date:  2021-10-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.